MET and non-small cell lung carcinoma: [30]BRAF appears to have a role as a predictive marker in patients with advanced melanoma disease [31, 32], with a rather limited therapeutic effect followed by resistance development in NSCLC patients.[33] There are reports [34–36] proposing a mechanism for MET and EGFR axis regulation mediated by miRNAs.